Effects of Fairytales on Preschool Children With Attention Deficit Hyperactivity Disorder

August 14, 2022 updated by: Taipei Medical University

Effects of Individualized Fairytales on Preschool Children With Attention Deficit Hyperactivity Disorder With Developmental Delay

Under traditional rehabilitation programs, investigate the additional effects of individualized fairytales on preschool children with Attention Deficit Hyperactivity Disorder with developmental delays.

Study Overview

Detailed Description

Thirty preschool children with Attention Deficit Hyperactivity Disorder and developmental delays will be enrolled in regular traditional rehabilitation programs.

They will be randomized to the intervention group and control group. The participants in the intervention group will receive an additional 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months. The participants of both groups will continue to receive the traditional rehabilitation programs.

Therapeutic effects, including attention, cognitive function, vocabulary function, physical functional performance, and quality of life at baseline, will be evaluated after 12 weeks of treatment and three months after the treatment.

The evaluator will be blinded to the group's allocation during the whole course of the intervention.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 111-01
        • Shin Kong Wu Ho-Su Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 6 years (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • preschool children with a diagnosis of Attention Deficit Hyperactivity Disorder and developmental delay, under regular traditional rehabilitation programs, intelligence quotient 70 or greater

Exclusion Criteria:

  • age less than 3 or greater than 6 of children diagnosed with Attention Deficit Hyperactivity Disorder and developmental delay, under regular traditional rehabilitation programs, intelligence quotient below 70

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Intervention group
traditional rehabilitation programs with additional individualized fairytales class
In addition to traditional rehabilitation programs, 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months, to preschool children with Attention Deficit Hyperactivity Disorder and developmental delays in regular traditional rehabilitation programs
NO_INTERVENTION: Control group
traditional rehabilitation programs without additional individualized fairytales class

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
changes of hyperactivity
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score assessed by Swanson, Nolan and Pelham questionnaire, higher score indicating greater hyperactivity
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
changes of attention
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score change by Conners Kiddie Continuous Performance Test, greater score indicating lower attention span
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of vocabulary
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score change by Receptive and Expressive Vocabulary Test, higher score indicating greater performance
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of sensory integration
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score change by Sensory Profile, 0-100, higher score indicating better sensory profile
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of intelligence
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score change by Wechsler Intelligence Scale for Children, the average score is 100, with a higher score indicating higher intelligence and a lower score indicating a lower level of intelligence
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of physical functional performance
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score assessed by Pediatric Outcome Data Collection Instrument, 0-100, a higher score indicating greater performance
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of quality of life
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score assessed by the Pediatric Quality of Life Inventory, 0-100, a higher score indicating a greater quality of life
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of family impact
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
score assessed by Child Health Questionnaire, parent form 28, 0-100, a higher score indicating better performance
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of walking time
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
walking time
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of stairs climbing time
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
climbing time
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of balance
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
one leg standing time
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
change of physical function
Time Frame: score change from baseline to 12 weeks of treatment, and 12 weeks after treatment
5 times sit to stand up
score change from baseline to 12 weeks of treatment, and 12 weeks after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

August 20, 2022

Primary Completion (ANTICIPATED)

June 30, 2023

Study Completion (ANTICIPATED)

June 30, 2023

Study Registration Dates

First Submitted

August 14, 2022

First Submitted That Met QC Criteria

August 14, 2022

First Posted (ACTUAL)

August 16, 2022

Study Record Updates

Last Update Posted (ACTUAL)

August 16, 2022

Last Update Submitted That Met QC Criteria

August 14, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Deficit Hyperactivity Disorder

Clinical Trials on Traditional rehabilitation programs with Individualized fairytales class

Subscribe